

Catherine Thieblemont

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/7152991/publications.pdf](https://exaly.com/author-pdf/7152991/publications.pdf)

Version: 2025-02-01

232

PR articles

13,773

PR citations

13055

59

PR h-index

14773

113

g-index

278

documents

19663

doc citations

8143

72

h-index

16557

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial. <i>Journal of Clinical Oncology</i> , 2024, 42, 538-549.	21.6	5
2	Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study. <i>Journal of Clinical Oncology</i> , 2024, 42, 769-773.	21.6	19
3	Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. <i>Bone Marrow Transplantation</i> , 2024, 59, 366-372.	3.3	20
4	Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. <i>Blood</i> , 2024, 143, 1713-1725.	4.2	83
5	Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial. <i>Journal of Clinical Oncology</i> , 2024, 42, 538-549.	21.6	0
6	Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial. <i>Journal of Clinical Oncology</i> , 2024, 42, 1612-1618.	21.6	31
7	Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years. <i>Blood Cancer Journal</i> , 2024, 14, .	7.9	19
8	Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. <i>Leukemia</i> , 2024, 38, 2653-2662.	10.4	87
9	High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2023, 41, 479-484.	21.6	41
10	Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN- γ is a major determinant of CD4+ CAR T-cell antitumor activity. <i>Nature Cancer</i> , 2023, 4, 968-983.	22.8	103
11	Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. <i>Nature Medicine</i> , 2023, 29, 2593-2601.	39.5	76
12	Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 24-33.	1.0	8
13	Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study. <i>Cancer</i> , 2022, , .	4.1	3
14	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	4.2	87
15	A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 1058-1069.	1.5	5
16	Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2022, 57, 431-439.	3.3	54
17	The Alternative RelB NF- κ B Subunit Exerts a Critical Survival Function upon Metabolic Stress in Diffuse Large B-Cell Lymphoma-Derived Cells. <i>Biomedicines</i> , 2022, 10, 348.	3.5	15
18	Deep Learning Approach to Automate TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas. <i>Diagnostics</i> , 2022, 12, 417.	3.0	18

#	ARTICLE	IF	PR CITATIONS
19	Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study. <i>Bone Marrow Transplantation</i> , 2022, 57, 627-632.	3.3	4
20	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. <i>Cancers</i> , 2022, 14, 791.	4.0	4
21	Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 629-639.	43.7	469
22	Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma. <i>Haematologica</i> , 2022, 107, 2163-2172.	4.1	2
23	Systematic review reveals urgent need to homogenize endpoints choices and definitions in marginal zone lymphomas trials. <i>Leukemia and Lymphoma</i> , 2022, 63, 1544-1555.	1.5	5
24	Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group. <i>Cancers</i> , 2022, 14, 1761.	4.0	1
25	Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. <i>Nature Medicine</i> , 2022, 28, 735-742.	39.5	241
26	Finding a consensus on time-to-event endpoints definitions in marginal zone lymphoma: A Delphi method. <i>Hematological Oncology</i> , 2022, 40, 1086-1089.	2.2	1
27	Comparing apples and oranges: The ZUMA-7, TRANSFORM and BELINDA trials. <i>Hematological Oncology</i> , 2022, 40, 1090-1093.	2.2	13
28	Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life experience of the French Network. <i>Bone Marrow Transplantation</i> , 2022, 57, 966-974.	3.3	24
29	Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL. <i>Leukemia and Lymphoma</i> , 2022, 63, 2063-2073.	1.5	19
30	Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3541.	2.6	11
31	A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 5995-6004.	5.1	31
32	A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. <i>Nature Medicine</i> , 2022, 28, 2145-2154.	39.5	311
33	Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. <i>Haematologica</i> , 2021, 106, 859-862.	4.1	20
34	Deep-Learning ¹⁸ F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 30-36.	5.6	120
35	Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA. <i>Blood</i> , 2021, 137, 2307-2320.	4.2	68
36	Characteristics of Lymphoma in Patients with Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 827-839.	1.3	24

#	ARTICLE	IF	PR CITATIONS
37	Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma. <i>Annals of Hematology</i> , 2021, 100, 979-986.	1.5	16
38	Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21). <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a005934.	1.5	2
39	Real-life targeted next-generation sequencing for lymphoma diagnosis over 1 year from the French Lymphoma Network. <i>British Journal of Haematology</i> , 2021, 193, 1110-1122.	2.4	13
40	Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 1700-1709.	3.3	15
41	Health-Related Quality of Life and Utility Outcomes with Selinexor in Relapsed/refractory Diffuse Large B-Cell Lymphoma. <i>Future Oncology</i> , 2021, 17, 1295-1310.	2.4	9
42	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/Cell lymphoma, nasal type: A French study from the Soci� Francophone de Greffe de Moelle et de Therapie Cellulaire (SFGM�C). <i>American Journal of Hematology</i> , 2021, 96, 834-845.	6.1	15
43	Aspects biologiques et th�rapeutiques des lymphomes de la zone marginale. <i>Revue Francophone Des Laboratoires</i> , 2021, 2021, 56-63.	0.1	0
44	Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. <i>Journal of Hematology and Oncology</i> , 2021, 14, .	30.9	15
45	Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 194, 690-700.	2.4	178
46	New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT. <i>Cancers</i> , 2021, 13, 3998.	4.0	28
47	Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. <i>Blood Advances</i> , 2021, 5, 2965-2968.	5.1	8
48	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6323-6332.	6.9	66
49	Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas. <i>Cancer Research</i> , 2021, 81, 5202-5216.	0.6	26
50	Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 195, 388-398.	2.4	103
51	Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years. <i>Cancers</i> , 2021, 13, 4503.	4.0	8
52	Long-term survival of patients with mantle cell lymphoma after autologous hematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e648-e657.	9.2	46
53	Radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1453-1465.	2.2	10
54	Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. <i>Nature Medicine</i> , 2021, 28, 325-332.	39.5	454

#	ARTICLE	IF	PR CITATIONS
55	Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	1.0	2
56	Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. <i>British Journal of Haematology</i> , 2020, 189, 84-96.	2.4	17
57	Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. <i>Haematologica</i> , 2020, 105, e33-e36.	4.1	36
58	Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 17-29.	10.2	301
59	Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. <i>Journal of Infection</i> , 2020, 80, 219-224.	2.9	13
60	Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. <i>Lancet Haematology</i> , 2020, 7, e798-e807.	9.2	19
61	Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 5607-5615.	5.1	347
62	NF- κ B in the New Era of Cancer Therapy. <i>Trends in Cancer</i> , 2020, 6, 677-687.	10.6	70
63	Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2371-2381.	1.8	6
64	CD19-directed CAR T-cell therapy in B-cell NHL. <i>Current Opinion in Oncology</i> , 2020, 32, 408-417.	2.2	32
65	Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. <i>Blood Advances</i> , 2020, 4, 5773-5784.	5.1	90
66	Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group. <i>Hematological Oncology</i> , 2020, 38, 446-455.	2.2	11
67	Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study. <i>Annals of Hematology</i> , 2020, 99, 1615-1625.	1.5	17
68	Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. <i>Blood Cancer Journal</i> , 2020, 10, .	7.9	46
69	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e511-e522.	9.2	285
70	Earlier Steroid Use with Axicabtagene Ciloleuce (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL). <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S101.	1.6	14
71	Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews. <i>PharmacoEconomics - Open</i> , 2020, 4, 575-591.	1.7	7
72	Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T3 phase IB trial of the LYSA. <i>Annals of Hematology</i> , 2020, 99, 1771-1778.	1.5	10

#	ARTICLE	IF	PR CITATIONS
73	Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. <i>Haematologica</i> , 2020, 105, 2592-2597.	4.1	39
74	Stabilization of β -catenin upon B-cell receptor signaling promotes NF- κ B target genes transcription in mantle cell lymphoma. <i>Oncogene</i> , 2020, 39, 2934-2947.	6.7	20
75	Lymphomas with kidney involvement: the French multicenter retrospective LyKID study. <i>Leukemia and Lymphoma</i> , 2020, 61, 887-895.	1.5	9
76	High total metabolic tumor volume at baseline predicts survival independent of response to therapy. <i>Blood</i> , 2020, 135, 1396-1405.	4.2	162
77	Impact of the COVID-19 Outbreak on the Management of Patients with Cancer. <i>Targeted Oncology</i> , 2020, 15, 249-259.	3.3	117
78	Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. <i>Lancet Haematology</i> , 2019, 6, e429-e437.	9.2	86
79	Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study. <i>Health and Quality of Life Outcomes</i> , 2019, 17, .	3.0	14
80	Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1561-1572.	4.7	6
81	Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study. <i>Cancer</i> , 2019, 125, 2291-2299.	4.1	22
82	GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors. <i>Cell Metabolism</i> , 2019, 29, 1243-1257.e10.	26.2	68
83	Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor. <i>Bone Marrow Transplantation</i> , 2019, 55, 613-622.	3.3	16
84	Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies. <i>Cancer Medicine</i> , 2018, 7, 539-548.	2.7	13
85	Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. <i>Leukemia</i> , 2018, 32, 1799-1803.	10.4	85
86	Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH). <i>Digestive and Liver Disease</i> , 2018, 50, 124-131.	2.4	31
87	Quantification of Idelalisib in Human Plasma by Ultra-Performance Liquid Chromatography Coupled to Mass Spectrometry in Negative Ionization Mode. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 237-244.	1.8	10
88	Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination. <i>Seminars in Hematology</i> , 2018, 55, 179-181.	3.2	7
89	Definition of a minimal genes set for mature lymphoid blood diseases. <i>Hematologie</i> , 2018, 24, 27-59.	0.0	4
90	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. <i>British Journal of Haematology</i> , 2018, 183, 755-765.	2.4	51

#	ARTICLE	IF	PR CITATIONS
91	Curing diffuse large B-cell lymphomas in elderly patients. <i>European Journal of Internal Medicine</i> , 2018, 58, 14-21.	2.9	13
92	An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. <i>Blood</i> , 2018, 132, 1486-1494.	4.2	31
93	Optimizing initial therapy in DLBCL. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 199-208.	1.8	17
94	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. <i>British Journal of Haematology</i> , 2018, 182, 807-815.	2.4	24
95	Intensive care unit admission in patients with T cell lymphomas: clinical features and outcome. <i>Annals of Hematology</i> , 2018, 98, 195-203.	1.5	8
96	Burden of illness of follicular lymphoma and marginal zone lymphoma. <i>Annals of Hematology</i> , 2018, 98, 175-183.	1.5	23
97	Clinical aspects and therapy of gastrointestinal MALT lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 109-117.	1.8	53
98	Conduire des études épidémiologiques après cancer en France: modalités, difficultés et propositions de solutions. Les enseignements de l'étude SIMONAL sur les toxicités tardives des traitements du lymphome non Hodgkinien. <i>Bulletin Du Cancer</i> , 2017, 104, 221-231.	0.6	3
99	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. <i>Blood</i> , 2017, 129, 2224-2232.	4.2	274
100	Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 43-54.	1.8	73
101	Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. <i>Annals of Oncology</i> , 2017, 28, 2169-2178.	10.2	243
102	Management of aggressive lymphoma in very elderly patients. <i>Hematological Oncology</i> , 2017, 35, 49-53.	2.2	10
103	BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial. <i>Annals of Oncology</i> , 2017, 28, 1042-1049.	10.2	26
104	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , 2017, 28, 1436-1447.	10.2	322
105	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 1250-1260.	43.7	380
106	A MALT lymphoma prognostic index. <i>Blood</i> , 2017, 130, 1409-1417.	4.2	174
107	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 399-406.	23.6	86
108	Hodgkin lymphoma in adolescent and young adults: insights from an adult tertiary single-center cohort of 349 patients. <i>Oncotarget</i> , 2017, 8, 80073-80082.	1.7	14

#	ARTICLE	IF	PR CITATIONS
109	Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma. Hematology American Society of Hematology Education Program, 2017, 2017, 371-378.	2.9	25
110	HHV-6 reactivation as a cause of fever in autologous hematopoietic stem cell transplant recipients. Journal of Infection, 2017, 75, 155-159.	2.9	17
111	Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting. Oncotarget, 2017, 8, 16243-16258.	1.7	8
112	VEGF121, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers. Oncotarget, 2017, 8, 90808-90824.	1.7	4
113	Tailoring treatment for MALT lymphoma patients: where do we stand now?. Oncotarget, 2017, 8, 114422-114423.	1.7	1
114	Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses. Oncotarget, 2016, 7, 83987-84002.	1.7	21
115	A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. British Journal of Haematology, 2016, 173, 722-730.	2.4	51
116	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. American Journal of Hematology, 2016, 91, 179-184.	6.1	47
117	Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica, 2016, 101, 336-345.	4.1	59
118	Optimizing therapy for nodal marginal zone lymphoma. Blood, 2016, 127, 2064-2071.	4.2	64
119	Radiothérapie des lymphomes malins non hodgkiniens localisés de type MALT (gastriques et de la Tj ETQq1 1 0.784314 rgBT /Oncologique, 2016, 20, 543-546.	1.3	3
120	European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma. Haematologica, 2016, 101, e407-e410.	4.1	46
121	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet, The, 2016, 388, 565-575.	52.8	373
122	Pulmonary mucosa-associated lymphoid tissue lymphoma revisited. European Respiratory Journal, 2016, 47, 1244-1260.	12.1	88
123	Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment. Leukemia and Lymphoma, 2016, 57, 2425-2428.	1.5	0
124	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematology, the, 2016, 3, e196-e204.	9.2	400
125	Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Annals of Oncology, 2016, 27, 390-397.	10.2	68
126	Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA. Annals of Oncology, 2016, 27, 1349-1350.	10.2	13

#	ARTICLE	IF	PR CITATIONS
127	Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. <i>Annals of Hematology</i> , 2016, 96, 253-259.	1.5	25
128	Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study. <i>Blood</i> , 2016, 128, 1213-1213.	4.2	9
129	Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group. <i>Blood</i> , 2016, 128, 145-145.	4.2	38
130	Temsirolimus in Combination with Three Different Immuno-Chemotherapy Regimens in Relapse and Refractory Mantle Cell Lymphoma, Final Results of the T3 Phase IB Trial of the Lysa Group. <i>Blood</i> , 2016, 128, 2987-2987.	4.2	1
131	First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa. <i>Blood</i> , 2016, 128, 471-471.	4.2	13
132	In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. <i>PLoS ONE</i> , 2016, 11, e0156384.	2.4	20
133	Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies. <i>Blood</i> , 2016, 128, 927-927.	4.2	0
134	Tolerance and Efficacy of L-Asparaginase during Induction of Extra-Nodal Natural Killer (NK/T) Lymphoma, Nasal Type, in Real-Life Experience. <i>Blood</i> , 2016, 128, 5351-5351.	4.2	0
135	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , 2015, 125, 1922-1931.	4.2	63
136	High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. <i>Blood</i> , 2015, 126, 604-611.	4.2	151
137	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2524.	17.1	161
138	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC13 lymphoC study. <i>American Journal of Hematology</i> , 2015, 90, 197-203.	6.1	87
139	Ibrutinib : applications cliniques et perspectives de développement dans les hémopathies malignes B. <i>Bulletin Du Cancer</i> , 2015, 102, S85-S90.	0.6	2
140	Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. <i>Lancet Haematology</i> , 2015, 2, e160-e165.	9.2	100
141	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , 2015, 20, 1149-1153.	3.5	60
142	Outcomes after intensive care unit admission of patients with newly diagnosed lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1240-1245.	1.5	24
143	Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma. <i>Annals of Hematology</i> , 2015, 94, 1859-1863.	1.5	4
144	Inhibitors of BCR signalling interrupt the survival signal mediated by the microenvironment in mantle cell lymphoma. <i>International Journal of Cancer</i> , 2015, 136, 2761-2774.	4.5	52

#	ARTICLE	IF	PR CITATIONS
145	Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2015, 56, 2025-2031.	1.5	7
146	Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2015, 51, 365-371.	3.3	51
147	Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies. <i>Clinical Pharmacokinetics</i> , 2015, 55, 397-405.	3.6	83
148	Analytical Performance of Nanostring's Companion Diagnostic (CDx) Lymphoma Subtyping Test (LST) with Diffuse Large B-Cell Lymphoma Core Needle Biopsy Samples. <i>Blood</i> , 2015, 126, 1481-1481.	4.2	1
149	Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 1532-1532.	4.2	5
150	Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Interim Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group. <i>Blood</i> , 2015, 126, 338-338.	4.2	20
151	Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study. <i>Blood</i> , 2015, 126, 517-517.	4.2	2
152	Are Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Occurring during the Course of Lymphoma (Ly) Always Therapy Related?. <i>Blood</i> , 2015, 126, 2886-2886.	4.2	1
153	Metabolic Tumor Volume Influences Response to Brentuximab-Vedotin in Relapsed Refractory Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 588-588.	4.2	0
154	Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. <i>Leukemia and Lymphoma</i> , 2014, 55, 1854-1860.	1.5	87
155	Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. <i>British Journal of Haematology</i> , 2014, 166, 390-400.	2.4	58
156	Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?. <i>Leukemia and Lymphoma</i> , 2014, 55, 2362-2367.	1.5	15
157	Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. <i>Seminars in Cancer Biology</i> , 2014, 24, 33-42.	14.1	89
158	Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2023-2030.	5.6	10
159	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naïve patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. <i>Lancet Oncology</i> , 2014, 15, 1019-1026.	26.0	250
160	Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases. <i>Annals of Hematology</i> , 2014, 94, 89-95.	1.5	21
161	GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF- κ B-dependent induction of HIF-1 α . <i>Leukemia</i> , 2014, 29, 1163-1176.	10.4	60
162	Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective LyMa Trial, a Lysa Study. <i>Blood</i> , 2014, 124, 146-146.	4.2	19

#	ARTICLE	IF	PR CITATIONS
163	Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study. <i>Blood</i> , 2014, 124, 1625-1625.	4.2	1
164	Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 3067-3067.	4.2	15
165	Promising Results of Ibrutinib in Three Patients with Secondary Central Nervous System Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 3105-3105.	4.2	2
166	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies. <i>Blood</i> , 2014, 124, 4417-4417.	4.2	8
167	A Phase Ib Study of Obinutuzumab Combined with Lenalidomide for Relapsed/Refractory Follicular B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 4458-4458.	4.2	8
168	Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with Waldenström's Macroglobulinemia / Lymphoplasmacytic Lymphoma (WM/LPL). a Risk Factor Analysis By the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party. <i>Blood</i> , 2014, 124, 678-678.	4.2	6
169	First Lymphoma Study Association workshops Deauville (France), 10th-12th October 2013 "À part 2". <i>Hematologie</i> , 2014, 20, 68-77.	0.0	0
170	Minimal Residual Disease Monitoring By 8-Color Flow Cytometry in Mantle Cell Lymphoma Is Complementary to Q-PCR Monitoring and Will Facilitate Pre-emptive Treatment: An EU-MCL and Lysa Study. <i>Blood</i> , 2014, 124, 1657-1657.	4.2	0
171	High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study. <i>Blood</i> , 2014, 124, 2526-2526.	4.2	2
172	Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Hépatologique. <i>British Journal of Haematology</i> , 2013, 162, 489-497.	2.4	104
173	A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial. <i>European Journal of Cancer</i> , 2013, 49, 2869-2876.	5.1	132
174	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 525-533.	26.0	286
175	Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). <i>Annals of Oncology</i> , 2013, 24, 1032-1037.	10.2	32
176	ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. <i>Annals of Oncology</i> , 2013, 24, 857-877.	10.2	279
177	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	10.2	203
178	At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK cell cytotoxicity. <i>European Journal of Immunology</i> , 2013, 43, 1383-1388.	3.2	22
179	Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. <i>Annals of Oncology</i> , 2013, 24, 1344-1351.	10.2	87
180	Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. <i>Annals of Oncology</i> , 2013, 24, 2612-2618.	10.2	32

#	ARTICLE	IF	PR CITATIONS
181	MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?. Blood, 2013, 121, 2165-2166.	4.2	26
182	Acute Kidney Injury in Patients with Newly Diagnosed High-Grade Hematological Malignancies: Impact on Remission and Survival. PLoS ONE, 2013, 8, e55870.	2.4	127
183	Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Annals of Hematology, 2013, 93, 233-242.	1.5	18
184	Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study. Blood, 2013, 122, 764-764.	4.2	8
185	Histological Characteristics Of Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. Results Of The French Lympho-C ANRS HC-13 Multicentric Study Of 133 Patients. Blood, 2013, 122, 3005-3005.	4.2	0
186	Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. Blood, 2013, 122, 77-77.	4.2	0
187	Prognostic Value Of Red Blood Cell and Platelet Transfusion In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study. Blood, 2013, 122, 3663-3663.	4.2	0
188	Rituximab For Hairy-Cell Leukemia (HCL): A Multicentric Retrospective Study Of 41 Cases. Blood, 2013, 122, 5308-5308.	4.2	0
189	BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma. Modern Pathology, 2012, 25, 805-814.	4.9	5
190	Lenalidomide in Diffuse Large B-Cell Lymphoma. Advances in Hematology, 2012, 2012, 1-8.	1.5	18
191	Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood, 2012, 119, 5126-5132.	4.2	180
192	Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Annals of Oncology, 2012, 23, 2380-2385.	10.2	52
193	MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood, 2012, 119, 4619-4624.	4.2	153
194	Ten-Year Relative Survival and Causes of Death in Elderly Patients Treated With R-CHOP or CHOP in the GELA LNH-985 Trial. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 151-154.	1.0	18
195	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCLnet). Blood, 2012, 120, 151-151.	4.2	53
196	Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study. Blood, 2012, 120, 152-152.	4.2	13
197	A Phase Ib Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL): The Ro-CHOP Study. Blood, 2012, 120, 1617-1617.	4.2	2
198	Lymphoma Occurring Over the Age of 90: Clinical Presentation and Outcome. Blood, 2012, 120, 1582-1582.	4.2	0

#	ARTICLE	IF	PR CITATIONS
199	Impact of Reduced Dose Intensity for Elderly Patients with Diffuse Large B-CELL Lymphoma Receiving R-CHOP Every 14 or 21 Days: An Analysis of the LNH03â€™6B GELA Study.. Blood, 2012, 120, 2723-2723.	4.2	1
200	Hairy Cell Leukemia: Evaluation of Long-Term Outcomes in 487 Patients. Blood, 2012, 120, 3921-3921.	4.2	0
201	Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2011, 12, 460-468.	26.0	504
202	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet, The, 2011, 378, 1858-1867.	52.8	336
203	Non-MALT marginal zone lymphoma. Current Opinion in Hematology, 2011, 18, 273-279.	2.8	25
204	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood, 2011, 117, 1595-1604.	4.2	185
205	Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma. Cancer Chemotherapy and Pharmacology, 2011, 68, 1135-1143.	2.2	6
206	SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood, 2011, 118, 37-43.	4.2	296
207	R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B. Blood, 2011, 118, 2632-2632.	4.2	5
208	Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999). Blood, 2011, 118, 268-268.	4.2	3
209	Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy. Blood, 2011, 118, 2718-2718.	4.2	2
210	An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,. Blood, 2011, 118, 3715-3715.	4.2	6
211	Early Results of a Phase Ib/II Dose-Escalation Trial of Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphomas (PTCL). Blood, 2011, 118, 2673-2673.	4.2	0
212	The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party. Blood, 2011, 118, 502-502.	4.2	1
213	Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood, 2010, 116, 1092-1104.	4.2	132
214	Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood, 2010, 116, 1479-1488.	4.2	186
215	Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood, 2010, 116, 2040-2045.	4.2	1,362
216	Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 262-269.	1.0	56

#	ARTICLE	IF	PR CITATIONS
217	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARAC Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL) Tj ETQq1 1 0.784314 rgBT /Ove	4.2	28
218	Interim-Positron Emission Tomography with [18F]Fluorodeoxyglucose (interim-PET) Evaluation In Mediastinal Lymphoma Including Hodgkin Lymphoma (HL) and Primary Mediastinal Large B-Cell Lymphoma (PMBL). Blood, 2010, 116, 2860-2860.	4.2	3
219	Second-line treatment paradigms for diffuse large B-cell lymphomas. Current Oncology Reports, 2009, 11, 386-393.	4.4	27
220	Phase I/II Study of IPH1101, Î³if T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.. Blood, 2009, 114, 1649-1649.	4.2	6
221	Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 884-884.	4.2	41
222	Indolent Mantle Cell Lymphoma (MCL): A Retrospective Detailed Clinical and Morphological Analysis of 21 Patients, with Histological, Cytological, Cytogenetic, Interphase Genetic, Immunoglobulin Gene, and Gene Expression Profiling Analysis.. Blood, 2008, 112, 1780-1780.	4.2	3
223	CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d'Étude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 2007, 25, 787-792.	21.6	247
224	Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer, 2005, 104, 1434-1441.	4.1	35
225	Clinical Presentation and Management of Marginal Zone Lymphomas. Hematology American Society of Hematology Education Program, 2005, 2005, 307-313.	2.9	105
226	Clinicopathologic Features of Waldenström's Macroglobulinemia and Marginal Zone Lymphoma: Are They Distinct or the Same Entity?. Clinical Lymphoma and Myeloma, 2005, 5, 220-224.	1.9	50
227	Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncology, The, 2003, 4, 95-103.	26.0	171
228	Outcome in Relation to Treatment Modalities in 48 Patients with Localized Gastric MALT Lymphoma: A Retrospective Study of Patients Treated During 1976-2001. Leukemia and Lymphoma, 2003, 44, 257-262.	1.5	29
229	Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood, 2003, 102, 2741-2745.	4.2	410
230	Treatment of Splenic Marginal Zone B-Cell Lymphoma: An Analysis of 81 Patients. Clinical Lymphoma and Myeloma, 2002, 3, 41-47.	1.9	151
231	Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood, 2000, 95, 802-806.	4.2	507
232	Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood, 2000, 95, 1950-1956.	4.2	287